The new Holy Grail of neurology? Plus, a common drug class for cognitive impairment, and answering an age old question in Alzheimer’s research
The layers of the Alzheimer’s onion keep peeling back, but we’ve yet to answer the simplest question: What causes it? That may have changed this week, as researchers set their sights on a new mutation that could lead to our best therapies yet. On top of that, we’re still short on therapies for tons of…